When performing univariate and multivariate (controlling for age, sex, UICC TNM stage, microsatellite instability (MSI), Epstein–Barr Virus (EBV)-, HER2- and cMET-status in the KIEL cohort, and in the KCCH cohort the aforementioned variables as well as tumor location, KRAS- and BRAF-mutation status, treatment type (surgery alone vs surgery followed by adjuvant chemotherapy), gastrectomy type and splenectomy status) Cox proportional hazards regression analyses, pathologist classification of diffuse and intestinal type GC was not related to survival (Suppl. This evidence concerns the gene KRAS and gastric cancer.